NeoPhotonics Corporation (NPTN)
Shares of NPTN touched a new 52-week high in after-hours trading Thursday as the company delivered a third consecutive quarter of non-GAAP profitability in its financial results
For the first quarter 2015, NPTN posted revenue of $81.4 million, a 19.4% increase year over year, and non-GAAP net income of $4.2 million, or $0.13 per diluted share, compared to a non-GAAP net loss of ($9.5) million, or ($0.30) per diluted share in the same quarter the prior year
According to its business outlook for the second quarter 2015, NPTN expects revenue to be in the range of $83 million to $89 million and non-GAAP diluted earnings per share to be in the range of $0.09 to $0.18.
NPTN is a leading designer and manufacturer of hybrid photonic integrated optoelectronic modules and subsystems for bandwidth-intensive, high-speed communications networks.
More about NeoPhotonics Corporation at www.neophotonics.com
**
Gevo, Inc. (GEVO)
The price of GEVO stock rose more than two-fold on Thursday and surged significantly in the extended session, continuing the positive momentum generated by the announcement that Alaska Airlines, a subsidiary of Alaska Air Group Inc. (ALK), will purchase the company's renewable jet fuel and fly the first-ever commercial flight on alcohol-to-jet fuel
GEVO's patented alcohol-to-jet fuel is a clean burning, homegrown, drop-in jet fuel, which has the potential to deliver aviation biofuels at scale and at competitive cost.
GEVO is a leading renewable technology, chemical products, and next generation biofuels company.
More about Gevo, Inc. at www.gevo.com
**
Sucampo Pharmaceuticals, Inc. (SCMP)
After the closing bell on Thursday, SCMP said that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for cobiprostone, a locally acting chloride channel activator, for the prevention of oral mucositis, a common complication of chemotherapy and for which there are no approved drugs in the U.S.
According to SCMP, the FDA has also accepted the company's Investigational New Drug (IND) application to initiate a phase 2 clinical trial of cobiprostone for the prevention of oral mucositis in patients suffering with head and neck cancer receiving concurrent radiation and chemotherapy.
Shares of SCMP climbed more than 5% following the announcement.
SCMP is a global biopharmaceutical company that is built on the ongoing pursuit of scientific innovation to improve the lives of patients.
More about Sucampo Pharmaceuticals, Inc. at www.sucampo.com
**
Crown Equity Holdings Inc. (OTCPK:CRWE)
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included Crestline, CA ( www.crestline.crwe-pr.com ) into the CRWE Network.
Crestline is a census-designated place in the San Bernardino Mountains of San Bernardino County, California. It is considered the gateway to the camping and recreation activities of the San Bernardino National Forest, because it is the closest mountain resort town to the cities.
Crestline had an estimated population in 2010 (U.S. Census) of 10,770, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S. and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The company's division CRWE Tube ( www.crwetube.com ) is expected to be integrated in all the CRWE Network
More about Crown Equity Holdings Inc. at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer